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Abstract
The American College of Medical Genetics and Genomics recently issued recommendations for
reporting incidental findings from clinical whole-genome sequencing and whole-exome
sequencing. The recommendations call for evaluating a specific set of genes as part of all whole-
genome sequencing/whole-exome sequencing and reporting all pathogenic variants irrespective of
patient age. The genes are associated with highly penetrant disorders for which treatment or
prevention is available. The effort to generate a list of genes with actionable findings is
commendable, but the recommendations raise several concerns. They constitute a call for
opportunistic screening, through intentional effort to identify pathogenic variants in specified
genes unrelated to the clinical concern that prompted testing. Yet for most of the genes, we lack
evidence about the predictive value of testing, genotype penetrance, spectrum of phenotypes, and
efficacy of interventions in unselected populations. Furthermore, the recommendations do not
allow patients to decline the additional findings, a position inconsistent with established norms.
Finally, the recommendation to return adult-onset disease findings when children are tested is
inconsistent with current professional consensus, including other policy statements of the
American College of Medical Genetics and Genomics. Instead of premature practice
recommendations, we call for robust dialogue among stakeholders to define a pathway to
normatively sound, evidence-based guidelines.
The American College of Medical Genetics and Genomics (ACMG) recently issued
recommendations for reporting of incidental findings when whole-genome sequencing
(WGS) or whole-exome sequencing (WES) is used in clinical practice.1 Like most
guidelines, these recommendations are intended to promote a standard of practice. The
article includes a disclaimer that notes “It may be prudent … to document in the patient’s
record the rationale for any significant deviation from these recommendations.”1 Yet
genome sequencing represents an emerging technology for which there is little accumulated
clinical experience or evidence. Many questions remain about its analytic performance and
optimal use, and outcome data are largely lacking. Furthermore, the ACMG
recommendations challenge accepted norms of patient autonomy and testing, especially in
children. In this article, we review four substantive concerns raised by the ACMG
recommendations and consider the related issues that should be addressed in constructive
dialogue among stakeholders, with the goal of defining a pathway to normatively sound,
evidence-based guidelines that can be broadly supported.
ESSENTIAL ELEMENTS OF THE ACMG RECOMMENDATIONS
The ACMG statement recommends that when WGS or WES is performed for any clinical
purpose in children or adults, a specified list of 56 genes associated with 24 inherited
conditions be assessed, in addition to the genomic information for which testing was sought.
The conditions were selected on the basis of high penetrance and clinical actionability.
Variants to be reported from this assessment include those known and predicted to be
pathogenic. The recommendations specify that these results, which are considered incidental
findings, should be generated by the laboratory and reported regardless of the age of the
patient. The recommendations reject the idea that the patient should be able to refuse these
findings, as the authors state that they “did not favor offering the patient a preference as to
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whether or not their clinician should receive a positive finding from the minimum list of
incidental findings described in these recommendations. We recognize that this may be seen
to violate existing ethical norms regarding the patient’s autonomy and “right not to know”
genetic risk information”.1
INCIDENTAL FINDINGS?
Incidental findings are frequently identified in the course of clinical practice. They derive
from the evaluation done to answer the clinical question and can range from unanticipated
skin findings on a physical examination to an unexplained mass on a radiological study.
When they occur, clinicians must consider their clinical significance and the appropriate
information to offer patients about them.
The evaluation of the 56 genes called for in the ACMG recommendations do not constitute
incidental findings in the usual sense of the term: they are more specific and intentional. The
recommendations call for purposeful analytic effort, above and beyond what is required to
answer the clinical question that prompted WGS/WES. If the 56 extra genes were not
analyzed, no finding(s) would be available to report, and the results of the extra analysis
represent information not sought by the patient.
At issue is not simply a debate about the application of “incidental findings” terminology to
analysis of the 56 genes, but more important, the implications of this added analysis for
clinicians and their patients. In emphasizing a specific list of genes to evaluate routinely as
part of WGS/WES, the recommendations endorse the decision not to interrogate other
genes. Among those other genes are some associated with highly penetrant conditions that
currently lack medical treatment, such as early-onset Alzheimer disease, and some
associated with conditions of low penetrance that are highly actionable, such as HFE-
associated hemochromatosis. In short, the list proposed in the ACMG recommendations is a
highly selected subset of the findings potentially obtainable from WGS/WES.
A selective approach to analysis of WGS/WES is both wise and necessary. Over time,
interrogation of DNA sequence will likely become increasingly automated, but the process
of whole-genome or whole-exome analysis will remain selective for the foreseeable future.
Attempting a full analysis of all 20,000 genes and clinically significant noncoding regions is
neither feasible in clinical care nor advisable, given variability in clinical significance and
difficulty in interpretation of clinical implications for much of the genome. Laboratories and
clinicians therefore choose to analyze certain portions of the genome and not others. In this
context, assessment of the 56-gene panel represents a distinct addition to the analytic
process, intended to achieve a specific purpose unrelated to the reason the test was ordered.
The ACMG recommendations suggest that once the sequence is in hand, “it becomes
relatively easy for a laboratory to report a limited number of variants for conditions that
could be medically important,”1 but evaluation of DNA sequence to identify pathogenic
variants is in fact labor intensive. Many findings represent rare or novel changes, and current
databases and scientific literature include errors and uncertainty. For example, Jarvik et al.2
recently reported an expert review of 1,000 research participants’ exomes for variants in 118
actionable genes. They reviewed 239 unique variants reported to be “disease causing” by the
Human Genome Mutation Database. On review of the primary literature, which took more
than 92 hours of expert time, only 9 variants in 8 participants met criteria for a pathogenic
mutation. These included 7 variants in genes on the ACMG list. This calculation does not
fully capture the effort involved in assessing variants. Jarvik et al.2 gained efficiency by
concurrent assessment of results from 1,000 subjects; these 239 variants were found 585
times in the sample. If 50% of exomes have variants that require evaluation, and these
evaluations require >20 min each, excluding double review and locating relevant literature,
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considerable time can be invested in the process of variant review for the discovery of
remarkably few diseasepredisposing variants.
The ACMG statement invokes the analogy of medical imaging as a related technology that
generates findings unrelated to the clinical question at hand.1 When a clinician orders a
magnetic resonance imaging study of the chest to evaluate a mass, for example, the
radiologist may note additional findings in the heart or lungs of potential clinical
significance, which will be included in the imaging report. Despite surface similarities, this
analogy is not entirely applicable to genome sequencing. The analysis used to generate the
clinically relevant magnetic resonance imaging result also generates the incidental finding,
in that the radiologist cannot avoid detecting the finding in the course of completing the
analysis required to address the clinical question. By contrast, in WGS/WES, the genes
relevant to the patient’s clinical presentation can be analyzed without including the 56-gene
panel (unless one or more of those genes is directly relevant to the patient’s clinical
presentation). In other words, the ACMG recommendations call for a deliberate add-on to
the analytic effort, focusing on evaluation of a small subset of genes deemed by the ACMG
to offer high potential for patient benefit.
It is not surprising that a technology as innovative as WGS/ WES lacks an exact analogy in
existing tests. Recognition of the deliberate decisions involved in generating ancillary or
secondary findings from this testing process can be helpful in developing appropriate testing
policies. In doing so, we suggest the need for further attention to limitations in current
evidence and incorporation of patient choice into the WGS/WES testing process.
EVIDENCE
The authors of the ACMG recommendations acknowledge that “there are insufficient data
on clinical utility to fully support these recommendations,”1 and accordingly encourage
periodic revisiting of their list. The recommendations are not accompanied by a technical
report or systematic review. However, the underlying rationale for the selection of the genes
is clear. The recommendations focus on inherited mutations in genes associated with highly
penetrant diseases for which interventions are available either to ameliorate the course of the
disease or to provide prevention opportunities. The current standard of practice in medical
genetics would call for offering testing to any patient with symptoms suggesting these
conditions.
Although the intent of the recommendations is commendable— to find treatable disease
before it is symptomatic—the lack of evidence for this use of genome sequencing suggests
that practice recommendations are premature. WGS/WES is currently done in a few well-
defined clinical circumstances:1,3 for patients with suspected genetic conditions for which
conventional genetic testing has failed to provide a diagnosis or for which a specific genetic
test is not available; as a tool for assessing genetically heterogeneous conditions; in cases in
which comparison of the patient’s genome with a tumor genome may offer a guide to
therapy; and in cases in which a genetic predisposition may exist to a rare cancer or group of
cancers. In all of these situations, a patient has a clinical condition or family history that
points to a specific clinical concern that the testing can address. With respect to the 56
additional genes to be routinely assessed, however, most patients undergoing WGS/WES
will be asymptomatic; nothing about their clinical presentation will necessarily point to the
need to assess these genes.
The potential to identify treatable or preventable genetic diseases at an early stage, in order
to improve outcome, is promising. 4 However, the approach stipulated in the ACMG
recommendations represents a form of opportunistic screening—not unlike checking a
person’s blood pressure when he or she seeks care for a respiratory infection. In other words,
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evaluation of the 56-gene panel has a different purpose from the analysis of sequence data
being done to address the patient’s presenting complaint. There are substantive concerns
about this use of sequencing data. Many of the 56 genes have only recently been identified,
and few of the disorders have a well-defined natural history. Mutations identified as
pathogenic have been seen for the most part in patients who presented with the disease,
leading to concerns about ascertainment bias.5,6 As a result, there is uncertainty about the
full spectrum of clinical manifestations associated with the mutations and about the
penetrance of risk genotypes among unselected patients. There is also a general lack of
controlled studies of interventions.
It is an established precept of public health that screening should be instituted only when
there is compelling evidence that it improves health outcomes in asymptomatic people.7 The
value of finding and treating hypertension, for example, has been rigorously assessed by
randomized trials that have defined pathogenic blood pressure levels and identified the
methods of treatment that can improve outcome.8,9 Stringent evidence requirements for
screening are important because of the potential for screening to lead to ambiguous results,
unnecessary work-up, iatrogenic harm, and false reassurance.7,10 To this point, the US
Preventive Services Task Force recommends against referral for BRCA counseling and
testing in asymptomatic women in the general population, based on a systematic review of
potential benefits and harms, and recommends instead that family history be assessed to
identify candidates for testing.11 Because there is no evidence on the outcomes of routine
testing of the 56-gene panel in unselected patients, we currently lack the basis to establish a
standard of practice; arguably, patients should be aware of the evidence limitations if they
are offered this screening option.
In considering what evidence would justify this approach, the first issue is test performance,
including the need to minimize false-positive and ambiguous findings.4 Positive and
negative predictive value may differ when an assay is used in an unselected population
versus in clinically based testing.12 Indeed, in cases in which the prior probability or
prevalence of disease is low (as is the case for most conditions referenced in the ACMG
recommendations), the positive predictive value will necessarily be lower than that in
situations of high disease prevalence.12 Adequate predictions of test performance will
require data from diverse populations; reliable estimates of the phenotypic spectrum for rare
genotypes will require accumulation of substantial WGS/WES data.
Screening also requires resources for timely and appropriate follow-up (including a
knowledgeable clinician workforce), and evidence that the screening process produces a net
benefit at an acceptable cost, taking into account potential harms.7,13–18 With opportunistic
screening, other demands on health providers’ time must be considered, including the
potential that the added screening may displace time for other interventions more relevant to
the patient seeking care.19 Research is thus needed to assess test performance; methods for
implementing genomic screening, including appropriate education and counseling measures;
and outcomes.
PATIENT CHOICE
The new ACMG recommendations define results from the 56-gene panel as a “minimum list
of incidental findings” to be generated without reference to patient preferences.1 This
position is contrary to an ACMG policy statement issued in 2012 on clinical genomic
sequencing that stated “patients should be given the option of not receiving certain or
secondary findings.” 3 The new policy raises serious ethical and legal concerns.
Competent adult patients have an established right to refuse medical interventions
recommended by their health-care providers. This right is present even when medical
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interventions are immediately lifesaving, for example, in the case of a Jehovah’s Witness
who refuses a blood transfusion in the face of a likely fatal hemorrhage. Unless patients’
decision-making capacity is impaired, or their refusal of therapy constitutes a threat to
public health, their right to refuse is virtually unlimited.20 The ACMG recommendations
propose, however, that any patient accepting WGS/WES for a clinical indication must also
accept analysis of the 56 genes identified in the recommendations, even when avoiding this
analysis would not impair the test’s capacity to address the clinical question that prompted
testing.
It may be that many patients undergoing WGS/WES would appreciate being offered the
additional screening proposed in the ACMG recommendations, on the actionability grounds
cited by the ACMG. However, choice matters. Patients may wish to decline the additional
analysis on a number of grounds, including the limited evidence on test performance and
outcomes. Concepts of shared decision making and respect for patient preferences argue for
offering meaningful choices wherever possible, with appropriate information to allow
patients to choose the best option for themselves.21 Furthermore, involving the patient in the
decision-making process helps the patient to anticipate potential results and the clinical
recommendations that follow if, for example, (in this case) testing of the 56 genes were
chosen. With appropriate evidence development, the choices offered could include
additional genes beyond those stipulated by ACMG recommendations, including tests for
autosomal-recessive carrier states or pharmacogenomics panels. But patients should be free
to decline any of these options.
If patients decline additional testing, it follows that the laboratory should not perform the
additional analyses. In a clarification statement issued after the recommendations, the
ACMG notes that “patients cannot opt out of the laboratory’s reporting of incidental
findings to the ordering clinician,” but anticipates that “the provider and patient will
participate in a shared decision-making process regarding the return of results.”22 This
ambiguous statement suggests that the anticipated shared decision making relates merely to
how and when pathogenic findings might be disclosed, not whether they will be disclosed.
Indeed, the ACMG clarification statement states that “not reporting … would be
unethical.”22 Beyond the fundamental problem of depriving patients of choice, the
additional costs involved in generating screening results from the 56 genes are a concern to
both patients and the health-care system. These costs should not be generated if the patient
does not wish to have the results.
An approach to practice that does not include the option to refuse additional genomic
findings could lead to the unintended consequence of patients’ refusing WGS/WES when it
is indicated. As an example, when WES is employed to detect a mutation in a child with a
suspected genetic disorder, testing of a parent–child trio is indicated. Under the ACMG
recommendations, all three persons would be required to accept testing for the 56 genes,
potentially leading a parent to be unwilling to participate. The requirement to return the
specified additional genetic information might thus interfere with the optimal care of a
patient, an inflexibility that would be ironic for a technology commonly presented as an
integral element of “personalized medicine.” Instead, robust debate is needed among all
stakeholders to identify strategies for offering appropriate choices to patients and the
research needed to assess those strategies.
TESTING IN CHILDREN
The ACMG’s recommendations raise particular concerns related to testing in children. An
important indication for WGS/WES is the work-up of individuals whose clinical
presentation strongly suggests a genetic condition for which conventional testing approaches
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are either unavailable or have failed to generate an answer. Many of these individuals will
be children. The recommendations state that the 56 genes should be assessed, and
pathogenic variants reported, irrespective of the age of the patient. This is a surprising
recommendation, which should be considered in the context of several other policy
documents on pediatric genetic testing generated over the past two decades, including a
recent joint statement from the ACMG and the American Academy of Pediatrics.23,24 The
consensus recommends avoiding testing children for known familial mutations for adult-
onset disease, on the premise that such testing is inconsistent with the best interests of the
child and the child’s future autonomy.
In calling for mandatory screening of all 56 genes in children receiving WGS/WES, the
ACMG recommendations argue that the screening process could benefit parents or other
family members. This rationale contrasts sharply with prevailing justifications of health care
for children in that it proposes testing a child to benefit others. The ACMG recommendation
statement makes it clear that the goal is to ensure the discovery of preventable disease risks,
on the theory that providing those benefits to parents is in the child’s interests.1,22 Although
true incidental findings (discovered in the analysis required to address the presenting clinical
question) should be offered to parents, intentional screening of a child aimed at putative
parental benefit is different. Our society does not mandate that competent adults obtain
medical information and/or treatment, even lifesaving treatment, just because they are
parents. To argue that parents must consent to information that may indirectly benefit them
is contrary to their right to refuse medical information and treatment. The rationale offered
for childhood testing in the recommendations, coupled with mandatory return regardless of
parental wishes, needs critical discussion and cannot be considered an appropriate basis for a
standard of practice at the present time.
MOVING TOWARD CONSENSUS
The ACMG recommendations were motivated by the goal of standardizing and optimizing
clinical genomic testing. Many well-intentioned clinicians, scientists, and other experts put
considerable effort into developing the recommendations, and they represent a valuable
starting point for deliberation. However, to date, this important conversation has not been
broad enough. In addition, active efforts are needed to engage all stakeholders in discussion
about the best steps forward. At a minimum, those stakeholders include public health and
genetics professionals; clinicians from primary care, general pathology, and other
specialties; policy makers; research and healthcare funders; bioethicists; and the health-care
consumers for whom genomic medicine is being developed. An important part of this
discussion should be about patient choice and how best to support it in the era of genomic
testing.
Gathering more evidence is also essential. WGS/WES is already finding a place in clinical
practice, as an expansion of existing genetic testing in certain defined clinical circumstances.
This approach to practice innovation represents an accepted strategy, but efforts are needed
to ensure that we learn as much as we can from early uses of the technology, through both
observation of patient experience and clinical outcomes and controlled interventions
designed to answer specific questions about the comparative effectiveness of WGS/WES
versus other testing approaches.
Studies designed to assess genotype penetrance, effectiveness of medical follow-up, and
personal and societal impact are particularly important for genome sequencing when the
analysis is undertaken to achieve a screening objective. In this use, careful consideration
must be given to potential harms, both to the individual tested and to the health-care system.
These harms include adverse labeling of healthy people as “sick,” unnecessary health-care
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expenditures, and iatrogenic complications.7,13–18 Because many of the conditions on the
ACMG list are rare, consensus will be needed regarding the level of evidence that is
sufficient to justify screening asymptomatic people.
Some relevant studies are already in process, funded by the National Human Genome
Research Institute’s Clinical Sequencing Exploratory Research.25 As part of the
investigation of clinical uses of genome sequencing, the Clinical Sequencing Exploratory
Research studies will evaluate the return of what it refers to as “unintended findings” and
explore related normative and policy questions. Each of the Clinical Sequencing Exploratory
Research studies defines unintended findings differently, and only a subset of these studies
involve randomized trials evaluating the process of returning these findings, but they will
provide valuable initial data to assess technical and clinical issues arising in evaluation and
return of findings unrelated to the clinical purpose for testing. In addition to clinical
sequencing studies, the Clinical Sequencing Exploratory Research consortium includes
smaller studies funded by the National Human Genome Research Institute Ethical, Legal,
and Social Implications research program that will provide additional data, insights, and
normative analyses relevant to guideline development. Another study recently funded by the
Ethical, Legal, and Social Implications program will design and pilot an assessment of a
preventive genomic testing protocol for high-risk mutations, similar to those 56 identified in
the ACMG recommendations, in a cohort of 1,000 adults.26 This study will provide
additional social, behavioral, and policy-relevant data on the question of genomic screening.
Because evidence will accumulate over time, any near-term approaches to genome-
sequencing practice should be provisional. Regular updating will be needed, with ongoing
discussion of the implications of emerging evidence and clinical experience. This evidence
will help stakeholders to assess the benefits and harms of opportunistic genomic screening
such as the ACMG recommendations describe. As part of this effort, there is a need for clear
processes for seeking patient consent, as well as a need for discussion of inclusion and
exclusion criteria to identify candidate variants to be evaluated under different clinical
scenarios, with systematic procedures to implement those criteria. The work of Goddard et
al.27 sponsored by the Evaluation of Genomic Applications in Practice and Prevention
working group represents an important step toward systematic evaluation.
Most important, the genetics community needs to ensure active debate of different uses of
genome sequencing, different approaches to ensuring and supporting patient choice, and the
ethical frameworks and evidence base needed to justify those uses. We need to invite other
perspectives into the conversation and create forums that allow for respectful exchange of
competing views. As an extraordinarily powerful and innovative technology, genome
sequencing has the potential for both benefit and harm to patients. Joint and dedicated effort
is needed to ensure positive and appropriate integration of genomics into clinical care.
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